Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

Rhea-AI Impact
Rhea-AI Sentiment
clinical trial fda approval
Rhea-AI Summary
Microbot Medical Inc. (MBOT) has filed an Investigational Device Exemption (IDE) application with the US Food and Drug Administration (FDA) for its LIBERTY® Endovascular Robotic Surgical System. The approval of the IDE application would allow the company to commence its pivotal human clinical trial in the United States. This marks an important milestone for the company in its journey to achieve FDA clearance for the surgical system.
  • None.
  • None.

The filing of an Investigational Device Exemption (IDE) with the FDA is a critical juncture for Microbot Medical, indicating a transition from preclinical research to human trials. The IDE allows a device to be used in a clinical study to collect safety and effectiveness data required for FDA approval. The approval of the IDE is a significant step in the development of the LIBERTY Endovascular Robotic Surgical System, as it validates the preclinical work done and sets the stage for the next phase of rigorous testing.

From a research perspective, the success of this system could potentially revolutionize endovascular surgeries by offering greater precision, reducing procedural times and minimizing radiation exposure to both patients and healthcare professionals. However, the road to FDA clearance is long and complex, involving several stages of clinical trials to demonstrate safety and efficacy. The results of these trials will be critical in determining the system's market potential and impact on patient care.

The IDE filing can have several financial implications for Microbot Medical. Firstly, the announcement may positively influence investor sentiment as it reflects progress in the company's product pipeline, potentially leading to an uptick in stock value. However, investors should also consider the costs associated with conducting pivotal human clinical trials, which are substantial and will likely increase the company's burn rate.

Moreover, the outcome of these trials is uncertain and any setbacks could negatively impact the company's financial health and stock performance. Investors should closely monitor the progress of the clinical trials and any communications from the FDA regarding the IDE application. The long-term financial impact will depend on the successful approval of the LIBERTY system, its adoption by healthcare providers and the competitive landscape of medical devices for endovascular surgery.

The endovascular surgical market is evolving rapidly with technological advancements and the introduction of robotic systems is poised to disrupt the current standard of care. A successful launch of the LIBERTY system could capture a significant market share, given the increasing demand for minimally invasive surgical options. Market analysts will be evaluating the potential adoption rate of the system, taking into account factors such as cost-effectiveness, ease of integration into existing workflows and training requirements for physicians.

Competitor analysis is also essential, as other companies may be developing similar technologies. The market response to the IDE filing and subsequent trial results will give indications of the system's commercial viability. It is also important to assess the reimbursement landscape, as this will influence the system's affordability and accessibility to patients. The impact on the stock market will correlate with how well Microbot Medical can capitalize on these market opportunities and navigate potential challenges.

The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this application

BRAINTREE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY® Endovascular Robotic Surgical System, announced that it has filed an Investigational Device Exemption (IDE) application with the US Food and Drug Administration (FDA). The IDE application follows the completion of multiple preclinical activities performed to provide preliminary safety and effectiveness information, and its approval by the FDA would allow the company to commence its pivotal human clinical trial in the United States.

“This is an important milestone for the company, and it is another step forward in our journey to achieve FDA clearance for the LIBERTY® Endovascular Robotic Surgical System,” said Harel Gadot, CEO, President and Chairman of Microbot Medical.  

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.

The LIBERTY Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY Endovascular Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures. Further information about Microbot Medical is available at

Safe Harbor

Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY, the outcome of its studies to evaluate LIBERTY, whether the Company’s core business focus program and cost reduction plan are sufficient to enable the Company to continue to focus on its LIBERTY technology while it stabilizes its financial condition and seeks additional working capital, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, any lingering uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michal Efraty

The ticker symbol for Microbot Medical Inc. is MBOT.

The IDE application is filed for the LIBERTY® Endovascular Robotic Surgical System to commence its pivotal human clinical trial in the United States.

Harel Gadot is the CEO, President, and Chairman of Microbot Medical Inc.
Microbot Medical Inc


MBOT Rankings

MBOT Latest News

MBOT Stock Data

Biological Product (except Diagnostic) Manufacturing
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing

About MBOT

microbot medical was founded with the vision of pioneering micro invasive surgery, transforming one of the biggest trends in healthcare - minimally invasive surgery (estimated to be close to $20b by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. through its unique platforms, microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. microbot’s virob platform is an autonomous advancing micro robot (aamr), less then 1mm in diameter, which has the ability to advance (forward/bac